Back to results
US 7,422,739 B2Granted
Anti-CD20 antibodies
AssigneeBiogen Idec Inc.
InventorsDarrell R. Anderson, Nabil Hanna, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
Life of this patent
Estimating the term…
Abstract
Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders.
Claims13
An immunologically active chimeric anti-CD20 antibody, wherein the antibody comprises a light chain variable region comprising the amino acid sequence shown as residues 23 to 128 of SEQ ID NO:
- 4 and a heavy chain variable region comprising the amino acid sequence shown as residues 20 to 140 of SEQ ID NO:
- 6.
An isolated anti-CD20 antibody, wherein the antibody comprises a light chain variable region comprising the amino acid sequence shown as residues 23 to 128 of SEQ ID NO:
- 4 and a heavy chain variable region comprising the amino acid sequence shown as residues 20 to 140 of SEQ ID NO:
- 6.
Dependencies are inferred from the claim text.